All news from Medical Toxicology

A Promising Biomarker Against Cancer

A study by the UPV / EHU-University of the Basque Country could facilitate the design of more effective tools for detecting tumors . The UPV / EHU's Department of Physical Chemistry and the Biofísika Institute have conducted a multidisciplinary study of the antigen that appears in 90% of cancers.

Celltrion And Teva Announces Rituximab Biosimilar

Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan® (rituximab) for the treatment of adult patients in three proposed indications.